Foley Hoag Advises Lead Investors in $15.6M Series D Financing of Cognoptix

October 01, 2014

Foley Hoag LLP recently represented Alopexx and Inventages in their $15.6 million Series D investment in Cognoptix, an emerging medical device company.

With this new funding, Cognoptix expects to complete the clinical development of its SAPPHIRE II eye test, designed to enable the early diagnosis of Alzheimer’s Disease (AD) patients via a beta-amyloid (A-beta) signature in their eyes. By detecting a specific fluorescent signature of ligand-marked A-beta in the supranucleus region of the human lens, SAPPHIRE II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable AD from a group of 20 age-matched healthy volunteers in a Phase II clinical trial.

Headquartered in Acton, Mass., Cognoptix is a privately held medical technology company focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease.

A Foley Hoag team consisting of Hemmie Chang, Amanda Vendig and Patrick Connolly advised Alopexx and Inventages. Original investor Launchpad Venture Group also participated in the round.